Innate Pharma SA
Camille Fos has extensive experience in research and development, particularly in protein generation and engineering. Currently serving as a Senior Specialist at Innate Pharma since September 2016, Camille leads the development of new binders and enhances antibody generation processes while managing projects and evaluating external technologies. Prior roles include Manager of R&D for Protein Engineering and CMC Development, where Camille supervised a team, planned tasks, and contributed to method development. Camille's earlier experience includes a postdoctoral fellowship at La Jolla Institute for Allergy and Immunology from January 2009 to December 2014, focusing on analyzing experimental data and developing collaborative projects in immunology. Camille holds a PhD in Immunology from Aix-Marseille University, with research on signaling pathways involving the ICOS/PI3-kinase axis during the doctoral studies.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.